Quantitative measurement of cell-free plasma DNA and applications for detecting tumor genetic variation and promoter methylation in a clinical setting.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Molecular Diagnostics

• Publication date

  2012-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jmoldx.2012.03.001PMID 22579630
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Continuous fluorescence monitoring of rapid cycle DNA amplification. 1997.

  2013cited by this paper
• A Modified Extraction Method of Circulating Free DNA for Epidermal Growth Factor Receptor Mutation Analysis

  2011cited by this paper
• Molecular and Cellular Pathobiology Cancer Research Cell-Free Nucleic Acids Circulating in the Plasma of Colorectal Cancer Patients Induce the Oncogenic Transformation of Susceptible Cultured Cells

  2010cited by this paper
• Is the role of circulating DNA as a biomarker of cancer being prematurely overrated?

  2010cited by this paper
• Real-time polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers

  2010cited by this paper
• Circulating DNA

  2008cited by this paper
• Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer

  2008cited by this paper
• Circulating nucleic acids (CNAs) and cancer--a survey.

  2007cited by this paper
• Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance.

  2007cited by this paper
• Circulating cell-free DNA: A novel biomarker for response to therapy in ovarian carcinoma

  2006cited by this paper
• Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma.

  2006cited by this paper
• Circulating DNA and Lung Cancer

  2006cited by this paper
• Genetic Variance Detection: technologies for pharmacogenomics

  2006cited by this paper
• Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients.

  2006cited by this paper
• Detection of free circulating Epstein-Barr virus DNA in plasma of patients with Hodgkin's disease

  2006cited by this paper
• Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays.

  2005cited by this paper
• Arrayed primer extension resequencing of mutations in the TP53 tumor suppressor gene: comparison with denaturing HPLC and direct sequencing.

  2005cited by this paper
• Effects of preanalytical factors on the molecular size of cell-free DNA in blood.

  2005cited by this paper
• Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients.

  2005cited by this paper
• Improved method for isolating cell-free DNA.

  2005cited by this paper
• Detection of Circulating Tumour DNA in the Blood (Plasma/Serum) of Cancer Patients

  2004cited by this paper
• Low value of detection of KRAS2 mutations in circulating DNA to differentiate chronic pancreatitis to pancreatic cancer

  2004cited by this paper
• Allelic Imbalance on 12q22-23 in Serum Circulating DNA of Melanoma Patients Predicts Disease Outcome

  2004cited by this paper
• Amount of DNA in plasma and cancer risk: A prospective study

  2004cited by this paper
• Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients

  2003cited by this paper
• Early p53 mutations in nondysplastic Barrett's tissue detected by the restriction site mutation (RSM) methodology

  2003cited by this paper
• Pyrosequencing for SNP genotyping.

  2003cited by this paper
• Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites.

  2003cited by this paper
• Effects of blood-processing protocols on cell-free DNA quantification in plasma.

  2003cited by this paper
• Changes in concentration of DNA in serum and plasma during storage of blood samples.

  2003cited by this paper
• Use of magnetic beads for plasma cell-free DNA extraction: toward automation of plasma DNA analysis for molecular diagnostics.

  2003cited by this paper
• Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation.

  2002cited by this paper
• Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosis

  2002cited by this paper
• p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients.

  2002cited by this paper
• Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer.

  2002cited by this paper
• DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.

  2001cited by this paper
• Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer.

  2001cited by this paper
• Clinical Chemistry 47:9 1607–1613 (2001) Molecular Diagnostics and Genetics Effects of Blood-Processing Protocols on Fetal and Total DNA Quantification in Maternal Plasma

  2001cited by this paper
• Relationship of p16 methylation status and serum alpha-fetoprotein concentration in hepatocellular carcinoma patients.

  2000cited by this paper
• Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids.

  2000cited by this paper
• Relationship of p16 Methylation Status and Serum α-Fetoprotein Concentration in Hepatocellular Carcinoma Patients

  2000cited by this paper
• Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.

  1999cited by this paper
• Detection of Pancreatic Carcinoma (Diagnostic Value of K-ras Mutations in Circulating DNA from Serum)

  1999cited by this paper
• Rapid clearance of fetal DNA from maternal plasma.

  1999cited by this paper
• Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features.

  1998cited by this paper
• Use of real-time quantitative PCR to compare DNA isolation methods.

  1998cited by this paper
• Continuous fluorescence monitoring of rapid cycle DNA amplification.

  1997cited by this paper
• Microsatellite alterations in serum DNA of head and neck cancer patients

  1996cited by this paper
• Lung cancer and circulating DNA.

  1986cited by this paper
• Free DNA in the serum of cancer patients and the effect of therapy.

  1977cited by this paper
• Circulating DNA as a Possible Factor in Oncogenesis

  1965cited by this paper

• Cell-Free DNA in the Pathogenesis and Therapy of Non-Infectious Inflammations and Tumors

  2022cites this paper
• Liquid biopsy in lung cancer management

  2022cites this paper
• Liquid biopsy: the value of different bodily fluids.

  2022cites this paper
• Liquid Biopsy, the hype vs. hope in molecular and clinical oncology.

  2021cites this paper
• Guidelines for pre-analytical conditions for assessing the methylation of circulating cell-free DNA

  2021cites this paper
• Two Reliable Methodical Approaches for Non-Invasive RHD Genotyping of a Fetus from Maternal Plasma

  2020cites this paper
• Pre-analytical issues in liquid biopsy – where do we stand?

  2020cites this paper
• Cell-free DNA and the monitoring of lymphoma treatment.

  2019cites this paper
• Circulating cell-free DNA does not harbour a diagnostic benefit in cats with feline diffuse iris melanomas

  2019cites this paper
• Clinical Validation of a Cell-Free DNA Gene Panel.

  2019cites this paper
• Exosomes-Associated DNA—New Marker in Pregnancy Complications?

  2019cites this paper
• Liquid Biopsy Diagnosis of CNS Metastases

  2019cites this paper
• Circulating cell-free DNA for non-invasive cancer management.

  2018cites this paper
• Circulating tumor DNA: an important tool in precision medicine for lymphoma

  2018cites this paper
• The value of cell‐free DNA for molecular pathology

  2018cites this paper
• Factors that influence quality and yield of circulating-free DNA: A systematic review of the methodology literature

  2018cites this paper
• Application and optimization of minimally invasive cell-free DNA techniques in oncogenomics

  2018cites this paper
• Integrating liquid biopsies into the management of cancer

  2017cites this paper
• The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review

  2017cites this paper
• Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.

  2017cites this paper
• Preanalytical blood sample workup for cell‐free DNA analysis using Droplet Digital PCR for future molecular cancer diagnostics

  2017cites this paper
• Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.

  2015cites this paper
• Do Circulating Tumor Cells, Exosomes, and Circulating Tumor Nucleic Acids Have Clinical Utility?: A Report of the Association for Molecular Pathology.

  2015cites this paper
• Establishment of PCR based methods for detection of ctDNA in blood

  2013cites this paper
• Cell-free DNA: characteristics, detection and its applications in myocardial infarction.

  2013cites this paper